• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

    8.750 +0.630 (+7.76%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,250,370
    Open 8.390
    Bid (Size) 8.620 (100)
    Ask (Size) 8.750 (100)
    Prev. Close 8.120
    Today's Range 8.230 - 9.160
    52wk Range 3.030 - 11.41
    Shares Outstanding 30,674,855
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Unusual volume stocks are being observed in Tuesday's session. ↗
    Via Chartmill
    These stocks are moving in today's session ↗
    Via Chartmill

    Performance

    YTD
    +46.1%
    +46.1%
    1 Month
    +92.3%
    +92.3%
    3 Month
    +45.1%
    +45.1%
    6 Month
    +1.7%
    +1.7%
    1 Year
    +164.4%
    +164.4%

    More News

    Read More
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    Why Sagimet Biosciences Stock Is Soaring Today ↗
    Via The Motley Fool
    Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study ↗
    Via Stocktwits
    These stocks are gapping in today's session ↗
    Via Chartmill
    Top movers in Monday's pre-market session ↗
    Via Chartmill
    News headline image
    Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Provides Strategic and Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Tuesday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Get insights into the top gainers and losers of Thursday's after-hours session. ↗
    Via Chartmill
    News headline image
    Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
    From Sagimet Biosciences Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Sagimet Biosciences Inc. - Series A Common Stock publicly traded?
    Yes, Sagimet Biosciences Inc. - Series A Common Stock is publicly traded.
    What exchange does Sagimet Biosciences Inc. - Series A Common Stock trade on?
    Sagimet Biosciences Inc. - Series A Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock?
    The ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock is SGMT on the Nasdaq Stock Market
    What is the current price of Sagimet Biosciences Inc. - Series A Common Stock?
    The current price of Sagimet Biosciences Inc. - Series A Common Stock is 8.750
    When was Sagimet Biosciences Inc. - Series A Common Stock last traded?
    The last trade of Sagimet Biosciences Inc. - Series A Common Stock was at 04/28/26 04:00 PM ET
    What is the market capitalization of Sagimet Biosciences Inc. - Series A Common Stock?
    The market capitalization of Sagimet Biosciences Inc. - Series A Common Stock is 268.40M
    How many shares of Sagimet Biosciences Inc. - Series A Common Stock are outstanding?
    Sagimet Biosciences Inc. - Series A Common Stock has 268M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.